More

    New Messenger RNA Cancer Treatment: When Will Clinical Trials Start?

    The German laboratory BioNTech will carry out tests to treat cancer based on the same technology used for vaccines against COVID-19

    Must Read

    TCRN STAFFhttps://www.TheCostaRicaNews.com
    Creating a Conscious alternative news network that we feel the world needs. Pura Vida!

    The German laboratory BioNTech will carry out a series of clinical trials of cancer treatments, which will be based on the same technology used for vaccines against COVID-19.

    Specifically, clinical trials will be conducted based on the same messenger RNA (mRNA) technology.It is intended to treat up to 10,000 patients with personalized mRNA-based cancer immunotherapies during 2023 in the UK.

    Cancer immunotherapies

    The initiative is part of an agreement with the British government on “Cancer immunotherapies, vaccines against infectious diseases and expansion of BioNTech in the UK.”

    In addition, a new research and development center of approximately 70 people will open in Cambridge and the firm will establish a regional headquarters in London.

    BioNTech CEO and Co-Founder UgurSahin said, “Our goal is to accelerate the development of immunotherapies and vaccines using technologies we have been researching for more than 20 years.”

    Personalized messenger RNA therapies

    Testing is expected to begin in the Northern Hemisphere fall of 2023.And the research is intended to enable cancer patients to have “early access to trials exploring personalized messenger RNA therapies,” they said in a statement.

    - Advertisement -
    - Advertisement -
    - Advertisement -

    Subscribe to our newsletter

    Get all the latest news, events, offers and special announcements.

    Latest News

    Costa Rica Will Host the First International Coffee Congress “CAFÉ WORLD SUMMIT

    The Café World Summit (CWS) is the first edition of an international congress that brings together the entire global...
    - Advertisement -

    More Articles Like This

    - Advertisement -
    Language »